Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Bought by Jane Street Group LLC

Jane Street Group LLC grew its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 118.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,704 shares of the biopharmaceutical company’s stock after acquiring an additional 21,512 shares during the quarter. Jane Street Group LLC owned approximately 0.15% of Inovio Pharmaceuticals worth $73,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Montreal Can acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $43,000. Northern Trust Corp lifted its holdings in shares of Inovio Pharmaceuticals by 6.4% in the 4th quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 13,269 shares during the last quarter. XTX Topco Ltd acquired a new position in Inovio Pharmaceuticals during the 4th quarter valued at approximately $96,000. Geode Capital Management LLC boosted its position in Inovio Pharmaceuticals by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 6,874 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in Inovio Pharmaceuticals during the 4th quarter worth $549,000. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $2.27 on Monday. Inovio Pharmaceuticals, Inc. has a one year low of $1.42 and a one year high of $12.33. The stock’s fifty day moving average is $1.86 and its 200-day moving average is $2.16. The firm has a market capitalization of $83.25 million, a price-to-earnings ratio of -0.71 and a beta of 1.34.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.01 million. Analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INO. Oppenheimer cut their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 14th. Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Finally, HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.75.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.